How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 58.3 | 58.3 | 65.9 | 69.4 | 69.4 | 69.4 | +11.0 |
| Healthcare | 28.1 | 28.1 | 20.7 | 17.2 | 17.2 | 17.2 | -10.9 |
| Financial Services | 7.0 | 7.0 | 6.3 | 7.3 | 7.3 | 7.3 | +0.3 |
| Chemicals | 1.3 | 1.3 | 1.7 | 2.1 | 2.1 | 2.1 | +0.7 |
| Digital | 1.1 | 1.1 | 1.3 | 1.5 | 1.5 | 1.5 | +0.4 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 9.09% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| LUPIN | Pharma | 5.83% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| LAURUSLABS | Pharma | 5.76% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| ABBOTINDIA | Pharma | 5.43% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| TORNTPHARM | Pharma | 5.27% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| IPCALAB | Pharma | 5.18% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| APOLLOHOSP | Healthcare | 4.66% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| JBCHEPHARM | Pharma | 4.38% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| FORTIS | Healthcare | 4.27% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| DIVISLAB | Pharma | 3.68% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| EMCURE | Pharma | 3.38% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| SBILIFE | Financial Services | 3.36% | 3 | — | 2 | 8 | 10 | 0/2 | -8.6% |
| ASTERDM | Healthcare | 3.15% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| ICICIPRULI | Financial Services | 2.69% | 2 | 1 | 8 | 6 | 5 | 0/2 | -13.6% |
| AUROPHARMA | Pharma | 2.62% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| GLENMARK | Pharma | 2.61% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| LALPATHLAB | Healthcare | 2.51% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| ACUTAAS | Chemicals | 2.07% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| ZYDUSLIFE | Pharma | 1.98% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| AJANTPHARM | Pharma | 1.61% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| IKS | Digital | 1.54% | 9 | 10 | 10 | 9 | 1 | 0/2 | +17.7% |
| CONCORDBIO | Pharma | 1.45% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
| MFSL | Financial Services | 1.22% | 4 | 1 | 6 | 5 | 4 | 0/2 | -8.0% |
| DRREDDY | Pharma | 1.20% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| CIPLA | Pharma | 1.16% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| POLYMED | Healthcare | 0.95% | 5 | 6 | 6 | 6 | 5 | 0/2 | +9.3% |
| GLAND | Pharma | 0.41% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| MANKIND | Pharma | 0.03% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
Performance · 1.0y
Over the last 1.0 years ₹100 in the fund grew to ₹104 (+4%), vs ₹97 for Nifty 500 (−3%) and ₹94 for Nifty 50 (−6%). Its relative-strength line ended at 112 vs Nifty 50 and 108 vs Nifty 500 — above 100, sustained outperformance.